ArticleBriefings in bioinformatics2026
Biochemical-knowledge-driven machine learning pipeline for generating potent antimicrobial peptides.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-driven discovery of antimicrobial peptides againstFrontiers in pharmacology · 2026Article
- Lab to codes: multimodel advanced AI-driven pipelines to drive antimicrobial peptide design for the post-antibiotic era.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The growing threat of antimicrobial resistance (AMR) necessitates the rapid discovery of novel antimicrobial peptides (AMPs) as alternative therapeutics. However, most computational approaches rely on binary AMP or non-AMP classification or permissive MIC thresholds (e.g. ≤128 μg/mL), offering limited biological interpretability and translational value. We present CVAE-BIO, a biochemical-knowledge-driven, multi-module pipeline for the discovery of AMPs targeting drug-resistant Escherichia coli as a model pathogen yet generalisable to other bacterial targets. The model integrates a conditional variational autoencoder (CVAE) constrained by key biochemical properties (MIC≤10 μg/mL, net charge > + 2, peptide length < 40 residues, instability index <40, and Boman index <0) with a Random Forest classifier trained on 30 biochemical descriptors. In vitro validation showed that 18.5% of generated peptides exhibited strong activity (MIC≤10 μg/mL), with 38.9% reaching MIC ≤50 μg/mL while maintaining key biochemical properties. Most validated novel peptides are narrow-spectrum AMP targeting E. coli. Wet-lab results also showed that highly active cationic-amphipathic AMPs are characterized by significantly low counts of tiny and small residues, suggesting that avoiding using these residues or limiting them to a maximum of 2 and 3, respectively, might improve the activity of AMP. Taking both antimicrobial activity and hemolytic toxicity into account, 9 peptides were identified as non-toxic and active AMP candidates. This explainable framework enables efficient AMP discovery under biochemical constraints and yields experimentally validated candidates with translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.